Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2005 6
2006 5
2007 2
2008 4
2009 4
2010 8
2011 11
2012 4
2013 7
2014 17
2015 19
2016 13
2017 14
2018 16
2019 21
2020 29
2021 29
2022 18
2023 18
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Results by year

Filters applied: . Clear all
Page 1
Author Correction: Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.
Sauriol SA, Carmona E, Udaskin ML, Radulovich N, Leclerc-Desaulniers K, Rottapel R, Oza AM, Lheureux S, Provencher DM, Mes-Masson AM. Sauriol SA, et al. Among authors: oza am. Sci Rep. 2024 May 1;14(1):10017. doi: 10.1038/s41598-024-60769-1. Sci Rep. 2024. PMID: 38693303 Free PMC article. No abstract available.
Corrigendum to Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences: Am J Obstet Gynecol 225 (2021) 658.e1-658.e9/Article 658.
Madariaga A, Bhat G, Wilson MK, Li X, Cyriac S, Bowering V, Hunt W, Gutierrez D, Bonilla L, Kasherman L, McMullen M, Wang L, Ghai S, Dhani NC, Oza AM, Lheureux S. Madariaga A, et al. Among authors: oza am. Am J Obstet Gynecol. 2024 Apr 27:S0002-9378(24)00475-7. doi: 10.1016/j.ajog.2024.03.039. Online ahead of print. Am J Obstet Gynecol. 2024. PMID: 38679558 No abstract available.
Methodical Manipulation of the TME in Ovarian Cancer.
Soberanis Pina P, Oza AM. Soberanis Pina P, et al. Among authors: oza am. Clin Cancer Res. 2024 Jan 5;30(1):12-16. doi: 10.1158/1078-0432.CCR-23-2365. Clin Cancer Res. 2024. PMID: 37939000
Heterogeneity and treatment landscape of ovarian carcinoma.
Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M, Sneha S, Oza AM. Veneziani AC, et al. Among authors: oza am. Nat Rev Clin Oncol. 2023 Dec;20(12):820-842. doi: 10.1038/s41571-023-00819-1. Epub 2023 Oct 2. Nat Rev Clin Oncol. 2023. PMID: 37783747 Review.
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
Grisham RN, Vergote I, Banerjee S, Drill E, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Cibula D, Moore KN, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Kristensen G, Clamp A, Farley J, Iyer G, Ray-Coquard I, Monk BJ. Grisham RN, et al. Among authors: oza am. Clin Cancer Res. 2023 Oct 13;29(20):4068-4075. doi: 10.1158/1078-0432.CCR-23-0621. Clin Cancer Res. 2023. PMID: 37581616 Free PMC article.
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.
Gonzalez-Ochoa E, Veneziani AC, Oza AM. Gonzalez-Ochoa E, et al. Among authors: oza am. Clin Med Insights Oncol. 2023 Jul 25;17:11795549231187264. doi: 10.1177/11795549231187264. eCollection 2023. Clin Med Insights Oncol. 2023. PMID: 37528890 Free PMC article. Review.
227 results